0 CHECKOUT

PRODUCT FILTERS

REGION

14
14
14
5

COUNTRY

14

CATEGORIES

  • 23
  • 4
  • 3
  • 3
  • 2
  • 2
  • 1

PRICE

28
29
33
37

PUBLISHED

0
2
6
37

PRODUCT TYPE

20
11
3
2
1

Search for: "BioMarin Pharmaceutical Inc-Deals & Alliances Report"

37 Products

BioMarin Pharmaceutical Inc. - SWOT, Strategy and Corporate Finance Report

BioMarin Pharmaceutical Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis,...

Published:  November 2013
Price:  From

BioMarin Pharmaceutical, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain...

Published:  May 2015
Price:  From

BioMarin Pharmaceutical Inc. - Product Pipeline Review - H2 2011

BioMarin Pharmaceutical Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “BioMarin Pharmaceutical Inc. - Product Pipeline Review - H2 2011” provides...

Published:  November 2011
Price:  From

Gene Therapy Partnering Terms and Agreements (3rd Edition)

The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies. Trends...

Published:  December 2014
Price:  From

Antibiotics Partnering Terms and Agreements

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends...

Published:  December 2013
Price:  From

Myelodysplastic Syndrome - Pipeline Review, H1 2014

Myelodysplastic Syndrome - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Myelodysplastic Syndrome - Pipeline Review, H1 2014’, provides an overview of the Myelodysplastic Syndrome’s therapeutic...

Published:  February 2014
Price:  From

Orphan Drugs - Global Strategic Business Report

This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts...

Published:  April 2015
Price:  From
Orphan Drugs - Global Strategic Business Report Orphan Drugs - Global Strategic Business Report - Product Thumbnail Image

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review,...

Published:  February 2014
Price:  From

Global Biosimilars Market, 2015 - 2025

Characterised by increased utility in chronic diseases and capital intensive manufacturing, the global biopharmaceutical market is expanding robustly. As the demand for biologics is increasing continuously,...

Published:  July 2015
Price:  From

Myelodysplastic Syndrome - Pipeline Review, H2 2012

Myelodysplastic Syndrome – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Myelodysplastic Syndrome - Pipeline Review, H2 2012', provides an overview of the Myelodysplastic Syndrome therapeutic...

Published:  August 2012
Price:  From

Vivus, Inc. (VVUS) - Financial and Strategic SWOT Analysis Review

Vivus, Inc. (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The publisher...

Published:  May 2015
Price:  From

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2012

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review,...

Published:  August 2012
Price:  From

Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review

Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The...

Published:  July 2015
Price:  From

Myelodysplastic Syndrome - Pipeline Review, H1 2012

Myelodysplastic Syndrome – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Myelodysplastic Syndrome - Pipeline Review, H1 2012', provides an overview of the Myelodysplastic Syndrome therapeutic...

Published:  January 2012
Price:  From

Daiichi Sankyo Company, Ltd - Product Pipeline Review - H2 2011

Daiichi Sankyo Company, Ltd – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Daiichi Sankyo Company, Ltd - Product Pipeline Review - H2 2011” provides data...

Published:  November 2011
Price:  From

Industry Report Card: Ratings Outlook Remains Stable For U.S. For-Profit Health Care Companies May 12

Abstract Standard & Poor's Ratings Services expects ratings for 2012 on the U.S. for-profit health care sector to be stable. Our view reflects adequate or better liquidity for a high majority of issuers,...

Published:  May 2012
Price: 

Leukemias - Pipeline Review, H1 2012

Leukemias – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Leukemias - Pipeline Review, H1 2012', provides an overview of the Leukemias therapeutic pipeline. This report provides information...

Published:  January 2012
Price:  From

Industry Report Card: Medicare Cuts Loom As A Senior Factor in U.S. Health Care Company Ratings Oct 11

Abstract Third-party funding of essential care, along with continued high margins for patented medical treatments, has protected many U.S. for-profit health care industry participants from the difficulties...

Published:  October 2011
Price: 

Industry Report Card: The 2011 Credit Prognosis For U.S. Health Care Companies Generally Is Favorable Jan 11

Abstract The prospect for an extended mid-single-digit revenue rise in U.S. health spending remains intact for 2011, based on the ongoing need for largely essential medical goods and services. According...

Published:  January 2011
Price: 

Industry Report Card: A Rash Of Activity For U.S. Speculative-Grade Health Care Companies Jul 10

Abstract With near-term industry visibility improving in the first half of 2010, yield-hungry investors appear to have an increasing interest in the sector's speculative-grade debt issuers. Consequently,...

Published:  July 2010
Price: 
Loading Indicator

Our Clients

  • Procter & Gamble Co.
  • Western Union Company
  • Volvo Car Corporation
  • Morgan Stanley
  • SAP SE
  • LG Corporation
  • Roche Diagnostics Ltd.